Naltrexone - FDA prescribing information, side effects and uses
of all these drugs, only two (methadone and naltrexone) are available to treat narcotic .. Morley, J.S. Structure-activity relationship of enkephalin-like peptides. The strength of the bond between the ligand (drug) and the receptor is The activity of naltrexone is believed to be due to both parent and the . A Look at the Morphinan Structure Activity Relationships of Six Popular Opiates. drug. Consequently, there have been no reports on U,H derivatives in the last 5 structure activity relationships, and pharmacology of alkoxymorphinans. “Synthesis of Novel Basic Skeletons Derived from Naltrexone,” by Hiroshi.
In the uncontrolled study, the patterns of abstinence and relapse were similar to those observed in the controlled studies. Naltrexone hydrochloride was not uniformly helpful to all patients, and the expected effect of the drug is a modest improvement in the outcome of conventional treatment. Treatment of Opioid Addiction Naltrexone hydrochloride has been shown to produce complete blockade of the euphoric effects of opioids in both volunteer and addict populations.
When administered by means that enforce compliance, it will produce an effective opioid blockade, but has not been shown to affect the use of cocaine or other non-opioid drugs of abuse. There are no data that demonstrate an unequivocally beneficial effect of Naltrexone hydrochloride on rates of recidivism among detoxified, formerly opioid-dependent individuals who self-administer the drug.
The failure of the drug in this setting appears to be due to poor medication compliance. The drug is reported to be of greatest use in good prognosis opioid addicts who take the drug as part of a comprehensive occupational rehabilitative program, behavioral contract, or other compliance-enhancing protocol.
Naltrexone hydrochloride, unlike methadone or LAAM levo-alpha-acetylmethadoldoes not reinforce medication compliance and is expected to have a therapeutic effect only when given under external conditions that support continued use of the medication. Indications and Usage for Naltrexone Naltrexone Hydrochloride Tablets USP are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids.
Naltrexone Hydrochloride Tablets USP have not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions.
Contraindications Naltrexone hydrochloride is contraindicated in: Patients receiving opioid analgesics. Patients currently dependent on opioids, including those currently maintained on opiate agonists e. Any individual who has failed the naloxone challenge test or who has a positive urine screen for opioids. Any individual with a history of sensitivity to Naltrexone hydrochloride or any other components of this product.
It is not known if there is any cross-sensitivity with naloxone or the phenanthrene containing opioids. Warnings Vulnerability to Opioid Overdose After opioid detoxification, patients are likely to have reduced tolerance to opioids.
As the blockade of exogenous opioids provided by Naltrexone hydrochloride wanes and eventually dissipates completely, patients who have been treated with Naltrexone hydrochloride may respond to lower doses of opioids than previously used, just as they would shortly after completing detoxification.
This could result in potentially life-threatening opioid intoxication respiratory compromise or arrest, circulatory collapse, etc. Cases of opioid overdose with fatal outcomes have been reported in patients after discontinuing treatment. Patients should be alerted that they may be more sensitive to opioids, even at lower doses, after Naltrexone hydrochloride treatment is discontinued.
There is also the possibility that a patient who is treated with Naltrexone hydrochloride could overcome the opioid blockade effect of Naltrexone hydrochloride. Although Naltrexone hydrochloride is a potent antagonist, the blockade produced by Naltrexone hydrochloride is surmountable. The plasma concentration of exogenous opioids attained immediately following their acute administration may be sufficient to overcome the competitive receptor blockade. This poses a potential risk to individuals who attempt, on their own, to overcome the blockade by administering large amounts of exogenous opioids.
Any attempt by a patient to overcome the antagonism by taking opioids is especially dangerous and may lead to life-threatening opioid intoxication or fatal overdose. Precipitated Opioid Withdrawal The symptoms of spontaneous opioid withdrawal which are associated with the discontinuation of opioid in a dependent individual are uncomfortable, but they are not generally believed to be severe or necessitate hospitalization.
However, when withdrawal is precipitated abruptly by the administration of an opioid antagonist to an opioid-dependent patient, the resulting withdrawal syndrome can be severe enough to require hospitalization. Symptoms of withdrawal have usually appeared within five minutes of ingestion of Naltrexone hydrochloride and have lasted for up to 48 hours. Mental status changes including confusion, somnolence and visual hallucinations have occurred. Significant fluid losses from vomiting and diarrhea have required intravenous fluid administration.
Review of postmarketing cases of precipitated opioid withdrawal in association with Naltrexone treatment has identified cases with symptoms of withdrawal severe enough to require hospital admission, and in some cases, management in the intensive care unit. To prevent occurrence of precipitated withdrawal in patients dependent on opioids, or exacerbation of a pre-existing subclinical withdrawal syndrome, opioid-dependent patients, including those being treated for alcohol dependence, should be opioid-free including tramadol before starting Naltrexone hydrochloride treatment.
An opioid-free interval of a minimum of 7 to 10 days is recommended for patients previously dependent on short-acting opioids. Patients transitioning from buprenorphine or methadone may be vulnerable to precipitation of withdrawal symptoms for as long as two weeks.
If a more rapid transition from agonist to antagonist therapy is deemed necessary and appropriate by the healthcare provider, monitor the patient closely in an appropriate medical setting where precipitated withdrawal can be managed. In every case, healthcare providers should always be prepared to manage withdrawal symptomatically with non-opioid medications because there is no completely reliable method for determining whether a patient has had an adequate opioid-free period.
A naloxone challenge test may be helpful; however, a few case reports have indicated that patients may experience precipitated withdrawal despite having a negative urine toxicology screen or tolerating a naloxone challenge test usually in the setting of transitioning from buprenorphine treatment.
Patients should be made aware of the risks associated with precipitated withdrawal and encouraged to give an accurate account of last opioid use. Patients treated for alcohol dependence with Naltrexone hydrochloride should also be assessed for underlying opioid dependence and for any recent use of opioids prior to initiation of treatment with Naltrexone hydrochloride.
Precipitated opioid withdrawal has been observed in alcohol-dependent patients in circumstances where the prescriber had been unaware of the additional use of opioids or co-dependence on opioids. Hepatotoxicity Cases of hepatitis and clinically significant liver dysfunction were observed in association with Naltrexone hydrochloride exposure during the clinical development program and in the postmarketing period. Transient, asymptomatic hepatic transaminase elevations were also observed in the clinical trials and postmarketing period.
Although clinically significant liver dysfunction is not typically recognized as a manifestation of opioid withdrawal, opioid withdrawal that is precipitated abruptly may lead to systemic sequelae, including acute liver injury. Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis.
Depression and Suicidality Depression, suicide, attempted suicide and suicidal ideation have been reported in the postmarketing experience with Naltrexone hydrochloride used in the treatment of opioid dependence. No causal relationship has been demonstrated.
In the literature, endogenous opioids have been theorized to contribute to a variety of conditions. Alcohol- and opioid-dependent patients, including those taking Naltrexone hydrochloride, should be monitored for the development of depression or suicidal thinking. Families and caregivers of patients being treated with Naltrexone hydrochloride should be alerted to the need to monitor patients for the emergence of symptoms of depression or suicidality, and to report such symptoms to the patient's healthcare provider.
Precautions General When Reversal of Naltrexone Hydrochloride Blockade is Required for Pain Management In an emergency situation in patients receiving fully blocking doses of Naltrexone hydrochloride, a suggested plan of management is regional analgesia, conscious sedation with a benzodiazepine, use of non-opioid analgesics or general anesthesia. In a situation requiring opioid analgesia, the amount of opioid required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.
A rapidly acting opioid analgesic which minimizes the duration of respiratory depression is preferred. The amount of analgesic administered should be titrated to the needs of the patient. Non-receptor mediated actions may occur and should be expected e. Irrespective of the drug chosen to reverse Naltrexone hydrochloride blockade, the patient should be monitored closely by appropriately trained personnel in a setting equipped and staffed for cardiopulmonary resuscitation.
Special Risk Patients Renal Impairment Naltrexone hydrochloride and its primary metabolite are excreted primarily in the urine, and caution is recommended in administering the drug to patients with renal impairment. Hepatic Impairment An increase in Naltrexone AUC of approximately 5- and fold in patients with compensated and decompensated liver cirrhosis, respectively, compared with subjects with normal liver function has been reported. These data also suggest that alterations in Naltrexone bioavailability are related to liver disease severity.
Information for Patients It is recommended that the prescribing physician relate the following information to patients being treated with Naltrexone hydrochloride: You have been prescribed Naltrexone hydrochloride as part of the comprehensive treatment for your alcoholism or drug dependence.
You should carry identification to alert medical personnel to the fact that you are taking Naltrexone hydrochloride. A Naltrexone hydrochloride medication card may be obtained from your physician and can be used for this purpose.
Carrying the identification card should help to ensure that you can obtain adequate treatment in an emergency. If you require medical treatment, be sure to tell the treating physician that you are receiving Naltrexone hydrochloride therapy.
You should take Naltrexone hydrochloride as directed by your physician. Advise patients that if they previously used opioids, they may be more sensitive to lower doses of opioids and at risk of accidental overdose should they use opioids after Naltrexone hydrochloride treatment is discontinued or temporarily interrupted. It is important that patients inform family members and the people closest to the patient of this increased sensitivity to opioids and the risk of overdose.
Opiophilia: Opioid Antagonists: Naloxone and Naltrexone
Advise patients that because Naltrexone hydrochloride can block the effects of opioids, patients will not perceive any effect if they attempt to self-administer heroin or any other opioid drug in small doses while on Naltrexone hydrochloride. Further, emphasize that administration of large doses of heroin or any other opioid to try to bypass the blockade and get high while on Naltrexone hydrochloride may lead to serious injury, coma or death.
Patients on Naltrexone hydrochloride may not experience the expected effects from opioid-containing analgesic, antidiarrheal, or antitussive medications. Patients should be off all opioids, including opioid-containing medicines, for a minimum or 7 to 10 days before starting Naltrexone hydrochloride in order to avoid precipitation of opioid withdrawal.
Ensure that patients understand that withdrawal precipitated by administration of an opioid antagonist may be severe enough to require hospitalization if they have not been opioid-free for an adequate period of time, and is different from the experience of spontaneous withdrawal that occurs with discontinuation of opioid in a dependent individual.
- There was a problem providing the content you requested
Advise patients that they should not take Naltrexone hydrochloride if they have symptoms of opioid withdrawal. Advise all patients, including those with alcohol dependence, that it is imperative to notify healthcare providers of any recent use of opioids or any history of opioid dependence before starting Naltrexone hydrochloride to avoid precipitation of opioid withdrawal. Finally antagonists such as naloxone bind to the receptor, but do not activate it at all.
The two most commonly used opioid antagonists are naloxone and naltrexone. Both are competitive antagonists, which means they work by competing for the receptor's binding site. The strength of the bond between the ligand drug and the receptor is known as the affinity.
Molecules with higher affinity for the receptor will replace those with lower affinity. Naloxone has a higher affinity for the mu opioid receptor than morphine, when administered it will replace the morphine bound to the receptor.
Because naloxone is an antagonist, the receptor will deactivate completely reversing the effects of the morphine. Both naltrexone and naloxone can be described as substituted derivatives of oxymorphone. The tertiary amine methyl-substituent is replaced with a longer chain of carbon atoms an allyl group. With naloxone the N-methyl group of oxymorphone is substituted with an N-propenyl group, with naltrexone this substitution is with an N-cyclopropylmethyl group.
The name naloxone has been derived from N-allyl and oxymorphone. While both antagonists have high oral bioavailability, they both undergo extensive first-pass metabolism. While naloxone is used primarily as an emergency antidote to opioid overdoses, naltrexone has been used as a medication to treat alcoholism and opioid addiction. Pharmacokinetics "When naloxone hydrochloride is administered intravenously the onset of action is generally apparent within two minutes; the onset of action is only slightly less rapid when it is administered subcutaneously or intramuscularly.
The duration of action is dependent upon the dose and route of administration of naloxone hydrochloride. Intramuscular administration produces a more prolonged effect than intravenous administration.
The requirement for repeat doses of naloxone hydrochloride, however, will also be dependent upon the amount, type and route of administration of the narcotic being antagonised.
Following parenteral administration naloxone hydrochloride is rapidly distributed in the body. It is metabolised in the liver, primarily by glucuronide conjugation and excreted in the urine. In a neonatal study the mean plasma half-life was observed to be 3.
The elimination half-life and time to maximum concentration are dose-independent. Although naloxone only works on opioids, it is the synergism of the drug combo that causes the overdose.